management

scientific advisors
and founders

clinical advisory board

board of directors

OUR TEAM

» management

Lissa Goldenstein - President and CEO
Lissa Goldenstein is an entrepreneurial executive with more than 28 years of experience bringing new technology to new markets. Prior to joining Artemis Health, Ms. Goldenstein served as the President and Chief Executive Officer of Argonaut Technologies, Inc (NASDAQ, AGNT) which was sold to Biotage AB of Sweden in June 2005. Prior to her CEO position, Ms. Goldenstein led the commercial activities for Argonaut from 1998, when it was an early stage, venture backed company through its Initial Public Offering in 2000. Argonaut Technologies was the leading provider of instruments and reagents that enable chemists in the pharmaceutical industry to find and develop new drugs. Prior to joining Argonaut, Ms. Goldenstein was Senior Vice President of Worldwide Sales, Marketing and Service with Molecular Simulations Incorporated, the largest provider of molecular modeling software for the pharmaceutical and chemical industries. From 1981 through 1991, Ms. Goldenstein directed sales activities for McDonnell Douglas Corporation, and was responsible for sales of the first CAD/CAM systems sold to designers in the building, engineering and manufacturing industries. Ms. Goldenstein has a B.S. in engineering from Pennsylvania State University. She is currently on the Board of Directors for Artemis Health, Argonaut Technologies and OtisMed Corporation.

Robert Nagle – Vice President Product Development
Mr. Nagle brings extensive product development expertise in microfluidic systems and life science instrumentation. He holds numerous patents in microfluidics, blood analysis and optics. Prior to joining Artemis Health, Mr. Nagle held the positions of Vice President of Product Development with Caliper Technologies and Vice President of Engineering with Turner Biosystems. He has led engineering and development activities for numerous innovative product lines including the first microfluidic systems from Caliper and the Abaxis Piccolo portable blood analyzer. He received his BA in physics from Wesleyan University with Masters and Engineer's degrees from Stanford University.

David Deng, M.D., Ph.D. – Director of Assay Development
Dr. Deng is an accomplished scientist with over 10 years experience in molecular research and diagnostic assay development. His expertise includes microfluidics, DNA microarrays and cell biology. Prior to joining Artemis Health, Dr. Deng was with Agilent Technologies where his research efforts focused on biomarker discoveries and clinical diagnostic assay developments. He has numerous peer-reviewed publications and patent applications for nucleic acid analysis and protein separations using microarrays and microfluidics. Dr. Deng is a graduate of Shanghai Second Medical University with an MD and an MS in Immunology and Infectious Disease, and a Ph.D. in Pharmacology from McGill University. He completed his Post-Doctoral Fellowship at University of California San Francisco.

Elizabeth Kerr, Ph.D. – Vice President of Marketing
Dr. Elizabeth Kerr brings over 10 years of strategic marketing experience as well as extensive scientific training to her role at Artemis Health. Prior to joining Artemis, Dr. Kerr was Director of Science and Medicine Marketing at Apple Inc. where she helped re-establish the Mac as the platform of choice for scientific and medical computing. Prior to Apple, Dr. Kerr held the position of Sr. Director of Marketing, Expression Analysis at Affymetrix Inc., where she was involved in the development, launch and marketing of the groundbreaking GeneChip™ expression array product line. Dr. Kerr holds a B.S. in Microbiology from the University of Maryland, College Park and a Ph.D. in Immunology from Stanford University, working in the lab of Dr. Mark M. Davis.

Myla Puyat – Senior Director of Finance and Administration
Ms. Puyat has over 18 years of management experience in Finance, Accounting, Human Resources, Legal and Office Administration ranging from early stage biotech and high-tech startups to Fortune 500 corporations. Prior to joining Artemis Health, Ms. Puyat was the Director of Finance & Administration of ForteBio, Inc. and Controller & Director of Operations of GeneTrol Biotherapeutics, Inc. By managing multiple functional areas, she has helped build the infrastructure of many companies from inception through revenue. Myla received her BS in Computer Engineering and an M.B.A. from Santa Clara University.

Melanie M. Mahtani, Ph.D. – Executive Advisor, Genetic Diagnostics
Dr. Melanie Mahtani is an experienced executive in the fields of human genetics, biomarker profiling, and personalized approaches to human disease management. Dr. Mahtani founded CompanionDx Consulting, a successful consulting practice for the molecular diagnostics and life science tools industries that provides strategic advisory, business planning and product strategy guidance. Prior to consulting, she was Vice President, Corporate Business Development at Panomics where she led product strategy for multiplexed gene expression products, and strategic partnering activities with major diagnostics, pharmaceutical and biotechnology companies. Dr. Mahtani was previously R&D Director at Amersham Biosciences (now GE Healthcare) where she launched a series of innovative products in high throughput genomic analysis. Dr. Mahtani holds a B.Sc. from Brown University and a Ph.D. in genetics from Stanford University. She was a postdoctoral fellow at the Whitehead Institute and MIT Genome Center where she led whole genome approaches to dissect the genetics of type 2 diabetes and other complex diseases.

top

» scientific advisors and founders

Diana W. Bianchi, M.D.
Dr. Diana W. Bianchi is the Natalie V. Zucker Professor of Pediatrics, Obstetrics and Gynecology and Vice-Chair for Research, Department of Pediatrics at Tufts University School of Medicine. She is recognized internationally for her multidisciplinary research in prenatal diagnosis and maternal fetal medicine, and particularly for her stewardship of the field of noninvasive, cell-based prenatal testing. She is the current President of the International Society of Prenatal Diagnosis, past President of the Perinatal Research Society, and Editor-in-Chief of the journal Prenatal Diagnosis. Dr. Bianchi has received numerous honors and awards for her innovative research and has authored over 180 peer-reviewed publications. Dr. Bianchi graduated magna cum laude from the University of Pennsylvania, received her M.D. from Stanford University, and completed residency training in Pediatrics at The Children’s Hospital, Boston. She completed clinical fellowships in the Harvard training programs in Medical Genetics and Newborn Medicine and is board-certified in all three specialties.

Ronald W. Davis, Ph.D.
Dr. Ronald Davis is a Professor of Genetics and Biochemistry at Stanford University and the Director of the Stanford Genome Technology Center. He received a B.S. in Chemistry from Eastern Illinois University, and a Ph.D. in Chemistry from California Institute of Technology. He is the recipient of many international and national awards for his contributions to genetics research and technology development related to genomics and proteomics. Among his awards: the United States Steel Award, Louis S Rosentiel Award for Distinguished Work in Basic Biomedical Research, Genetics Society of America Award, and Chiron Biotechnology Research Award. He was elected to the National Academy of Sciences (Genetics) in 1983. Dr. Davis is a leader in the development and application of many critical technologies utilized in genomics and proteomics research. He is also a world leader in the burgeoning field of single nucleotide polymorphisms (SNPs).

Ronald G. Tompkins, M.D., ScD
Dr. Ronald Tompkins is the John Francis Burke Professor of Surgery at the Harvard Medical School, the Chief of the Trauma, Burns & Surgical Critical Care Service of the Massachusetts General Hospital (MGH), and the Chief of Staff of the Shriners Hospitals for Children-Boston. He received a B.S. degree in Chemistry from Tulane University, an M.D. degree from Tulane Medical School, and a ScD degree in medical and chemical engineering from the Massachusetts Institute of Technology (MIT). Dr. Tompkins has served on scores of national committees and received multiple honors including a fellowship from the American Institute for Medical and Biological Engineering and an honorary M.A. from Harvard University, and he is a senior director of the American Board of Surgery. Dr. Tompkins has published more than 250 contributions to the medical literature. His research interests include the metabolic and inflammatory responses to injury and tissue engineering.

Mehmet Toner, Ph.D.
Dr. Mehmet Toner is a Professor of Bioengineering at the Harvard Medical School and the Director of the Microsystems Bioengineering Laboratory at Massachusetts General Hospital. He received a B.S. degree in Mechanical Engineering from Istanbul Technical University, M.S. degree in Mechanical Engineering from MIT, Ph.D. in Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology. Dr. Toner is internationally recognized in the applications of cell-based microsystems technology in biology and medicine and in tissue engineering and cryopreservation. He has published more than 150 scientific papers in engineering, biological, and clinical journals. Dr. Toner was the recipient of the YC Fung Young Faculty Award in Bioengineering, the Taplin Faculty Fellow Award of Harvard and MIT, and of a fellowship at the American Institute of Medical and Biological Engineering.

Martin A. Schmidt, Ph.D.
Dr. Martin Schmidt is a Professor in the MIT Department of Electrical Engineering and Computer Science, and the Director of the MIT Microsystems Technology Laboratory (MTL). He received a B.S. degree in Electrical Engineering from Rensselaer Polytechnic Institute, and M.S. and Ph.D. degrees in Electrical Engineering from MIT. Dr. Schmidt is an internationally recognized leader in microsystems engineering, in general, and its applications in biology, in particular. He has organized and chaired many international meetings in the general area of micro-sensors and actuators, microtonal analysis systems, and bio-microelectromechanical systems. He has extensively published his technological developments in prestigious journals, including the Journal of Microelectromechanical Systems, Journal of Biomechanical Engineering, and Biophysical Journal.

top

» clinical advisory board

Alfred Z. Abuhamad, M.D.
Dr. Alfred Abuhamad is Mason C. Andrews Professor of Obstetrics and Gynecology, Chair of the Department of Obstetrics and Gynecology, Director of the Division of Maternal Fetal Medicine and Associate Dean for Clinical Affairs at Eastern Virginia Medical School. Dr. Abuhamad is known internationally for his expertise in maternal-fetal medicine and obstetrical ultrasound, and for his innovative clinical research, including in the diagnosis of fetal cardiovascular problems in early pregnancy.
He is a member of the Nuchal Translucency Oversight Committee, is active on the editorial boards of several journals, and serves on the American Institute of Ultrasound in Medicine’s Board of Governors. Dr. Abuhamad completed his Maternal-Fetal Medicine fellowship at the University of Miami School of Medicine, and his clinical fellowship at Yale University School of Medicine in Ultrasound and Prenatal Diagnosis. Dr. Abuhamad is board certified in Obstetrics and Gynecology and holds is subspecialty certification from the American Board of Maternal-Fetal Medicine.

Mary D’Alton, M.D.
Dr. Mary D'Alton is the Willard C. Rappleye Professor and Chair of the Department of Obstetrics and Gynecology at Columbia University College of Physicians and Surgeons. As a recognized leader in maternal fetal medicine, she has created the Center for Prenatal Pediatrics, a multidisciplinary team approach to manage pregnancies diagnosed with fetal malformations. Dr. D'Alton was principal investigator for the historic NICHD FASTER trial and member of the NICHD Council. Dr. D’Alton is past President of the Society for Maternal Fetal Medicine, and has been honored by the Society with a Lifetime Achievement Award. She currently serves as Secretary for the American Gynecological and Obstetrics Society, Editor of Seminars in Perinatology, and Editorial Board member of the Green Journal. Dr. D’Alton received her M.D. from the National University of Ireland, and completed residency training at the University of Ottawa. She has completed fellowships in Maternal-Fetal Medicine at Tufts and Yale Universities. Dr. D’Alton is board certified in Obstetrics and Gynecology as well as Maternal Fetal Medicine.

James D. Goldberg, M.D.
Dr. Jim Goldberg is Medical Director at San Francisco Perinatal Associates. Dr. Goldberg is a founding fellow of the American College of Medical Genetics. He was previously Associate Professor of Clinical Obstetrics, Gynecology Reproductive Sciences, and Director of the Reproductive Genetics Unit at the University of California, San Francisco (UCSF) and subsequently co-director of the Prenatal Diagnosis Center at California Pacific Medical Center. Dr. Goldberg specializes in prenatal diagnosis, including CVS, amniocentesis, and genetic screening for a variety of indications. He has published extensively in the area of prenatal diagnosis and serves on committees which establish national policy for nuchal translucency screening. Dr. Goldberg received his M.D. from the University of Minnesota at Minneapolis, and completed fellowships at UCSF in Obstetrics and Gynecology, and the Mount Sinai School of Medicine, New York in Maternal-Fetal Medicine and Genetics. Dr. Goldberg is board certified in Obstetrics and Gynecology, Maternal-Fetal Medicine, and Medical Genetics.

Lawrence D. Platt, M.D.
Dr. Larry Platt is Professor of Obstetrics and Gynecology at the David Geffen School of Medicine at UCLA and Director of the Center for Fetal Medicine and Women’s Ultrasound in Los Angeles. He is past President of the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), and recipient of its highest honor, the Ian Donald Gold Medal Award. Dr. Platt has been elected to numerous professional organizations including the Society for Gynecologic Investigation and the American Gynecologic and Obstetrical Society. He is past President the American Institute of Ultrasound in Medicine and of the Los Angeles OB-GYN Society, Treasurer of the Maternal Fetal Medicine Foundation, and board member of the Society for Maternal Fetal Medicine. Dr. Platt has published extensively. He serves on the Board of Directors of InSightec and Diagnostic Technologies. Dr. Platt received his M.D. from Wayne State University, and completed his residency in Obstetrics and Gynecology and fellowship in Maternal-Fetal Medicine. He is board certified in Obstetrics and Gynecology and Maternal-Fetal Medicine.

top

» board of directors

Jeff Bird, M.D., Ph.D.
Jeff Bird joined Sutter Hill Ventures in 2002. As a Managing Director, he focuses on investment opportunities in healthcare, including biotechnology and medical devices. Dr. Bird came to Sutter Hill after 14 years in the biotechnology industry. Jeff was a founding member of Gilead Sciences where he worked from 1988 to 1990 and 1992 to 2000, most recently as Senior Vice President, Business Operations. He was primarily responsible for several alliances with major pharmaceutical companies and helped Gilead to acquire NeXstar. Direct sales in the US and Europe were also part of his responsibilities. Jeff received a degree in Biological Sciences from Stanford University in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D.in 1992 from Stanford Medical School.

Bill Ericson
Bill Ericson joined Mohr Davidow Ventures in 2000. As a managing partner, his investment focus is life sciences and software. He works closely with a cross-discipline team of leading scientists, researchers and entrepreneurs applying technology solutions to life sciences and health care in non-traditional ways. Mr. Ericson came to MDV after 10 years of working with and investing in entrepreneurs and early stage companies. During that time, he served as a board member of a number of life sciences and software companies, both public and private. Bill was a member of the founding team of Rosetta Inpharmatics and served on the Board of Directors until its acquisition by Merck in 2001.

Michael Hunkapiller, PhD.
Michael Hunkapiller joined Alloy in 2004 after 21 years at Applied Biosystems (NYSE: ABI), which he helped grow from startup to almost $2 billion in annual revenues supplying instrument and reagent systems for life science research. At ABI, he held several positions, most recently as President and General Manager. He was also a founder of ABI's sister company Celera Genomics (NYSE: CRA) and Senior Vice President of Applera Corporation (their parent company). Prior to joining ABI, Mike was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University in 1970 and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech in 1974. He has authored more than 100 scientific publications, is an inventor on more than two dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research, including the development of the automated DNA sequencing systems used to sequence the human genome. Mike is currently on the board of directors of Codon Devices, Fluidigm, and Pacific Biosciences.

top